HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A prospective randomized trial of four three-drug regimens in the treatment of disseminated Mycobacterium avium complex disease in AIDS patients: excess mortality associated with high-dose clarithromycin. Terry Beirn Community Programs for Clinical Research on AIDS.

Abstract
The optimal regimen for treatment of Mycobacterium avium complex (MAC) disease has not been established. Eighty-five AIDS patients with disseminated MAC disease were randomized to receive a three-drug regimen of clarithromycin, rifabutin or clofazimine, and ethambutol. Two dosages of clarithromycin, 500 or 1,000 mg twice daily (b.i.d.), were compared. The Data and Safety Monitoring Board recommended discontinuation of the clarithromycin dosage comparison and continuation of the rifabutin vs. clofazimine comparison. After a mean follow-up of 4.5 months, 10 (22%) of 45 patients receiving clarithromycin at 500 mg b.i.d. had died (70 deaths per 100 person-years) compared with 17 (43%) of 40 patients receiving clarithromycin at 1,000 mg b.i.d. (158 deaths per 100 person-years) (relative risk, 2.43; 95% confidence interval, 1.11-5.34; P = .02). After 10.4 months, 20 (49%) of 41 patients receiving rifabutin had died (81 deaths per 100 person-years) compared with 23 (52%) of 44 patients receiving clofazimine (94 deaths per 100 person-years) (relative risk, 1.20; 95% confidence interval, 0.65-2.19; P = .56). Bacteriologic outcomes were similar among treatment groups. In treating MAC disease in AIDS patients, the maximum dose of clarithromycin should be 500 mg b.i.d.
AuthorsD L Cohn, E J Fisher, G T Peng, J S Hodges, J Chesnut, C C Child, B Franchino, C L Gibert, W El-Sadr, R Hafner, J Korvick, M Ropka, L Heifets, J Clotfelter, D Munroe, C R Horsburgh Jr
JournalClinical infectious diseases : an official publication of the Infectious Diseases Society of America (Clin Infect Dis) Vol. 29 Issue 1 Pg. 125-33 (Jul 1999) ISSN: 1058-4838 [Print] United States
PMID10433575 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Anti-Bacterial Agents
  • Antibiotics, Antitubercular
  • Rifabutin
  • Clofazimine
  • Clarithromycin
Topics
  • AIDS-Related Opportunistic Infections (drug therapy, microbiology, mortality)
  • Adult
  • Anti-Bacterial Agents (adverse effects, therapeutic use)
  • Antibiotics, Antitubercular (adverse effects, therapeutic use)
  • Clarithromycin (adverse effects, therapeutic use)
  • Clofazimine (adverse effects, therapeutic use)
  • Dose-Response Relationship, Drug
  • Drug Therapy, Combination (adverse effects, therapeutic use)
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Mycobacterium avium Complex
  • Mycobacterium avium-intracellulare Infection (drug therapy, microbiology, mortality)
  • Patient Compliance
  • Prospective Studies
  • Rifabutin (adverse effects, therapeutic use)
  • Survivors
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: